<?xml version="1.0"?>
<oembed><version>1.0</version><provider_name>Brakke&#x54A8;&#x8BE2;&#x7F51;&#x7AD9;</provider_name><provider_url>https://brakkeconsulting.com/zh</provider_url><title>News from Brakke Consulting</title><type>rich</type><width>600</width><height>338</height><html>&lt;blockquote class="wp-embedded-content" data-secret="QC8pryZZNd"&gt;&lt;a href="https://brakkeconsulting.com/zh/20003/"&gt;2005&#x5E74;10&#x6708;21&#x65E5;&#x52A8;&#x7269;&#x5065;&#x5EB7;&#x65B0;&#x95FB;&#x4E0E;&#x7B80;&#x62A5;&lt;/a&gt;&lt;/blockquote&gt;&lt;iframe sandbox="allow-scripts" security="restricted" src="https://brakkeconsulting.com/zh/20003/embed/#?secret=QC8pryZZNd" width="600" height="338" title="&#x300A;2005&#x5E74;10&#x6708;21&#x65E5;&#x52A8;&#x7269;&#x5065;&#x5EB7;&#x65B0;&#x95FB;&#x4E0E;&#x7B80;&#x62A5;&#x300B;&#x2014;Brakke&#x54A8;&#x8BE2;&#x7F51;&#x7AD9;" data-secret="QC8pryZZNd" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"&gt;&lt;/iframe&gt;&lt;script type="text/javascript"&gt;
/* &lt;![CDATA[ */
/*! This file is auto-generated */
!function(d,l){"use strict";l.querySelector&amp;&amp;d.addEventListener&amp;&amp;"undefined"!=typeof URL&amp;&amp;(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&amp;&amp;!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i&lt;o.length;i++)o[i].style.display="none";for(i=0;i&lt;a.length;i++)s=a[i],e.source===s.contentWindow&amp;&amp;(s.removeAttribute("style"),"height"===t.message?(1e3&lt;(r=parseInt(t.value,10))?r=1e3:~~r&lt;200&amp;&amp;(r=200),s.height=r):"link"===t.message&amp;&amp;(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&amp;&amp;n.host===r.host&amp;&amp;l.activeElement===s&amp;&amp;(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r&lt;s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document);
//# sourceURL=https://brakkeconsulting.com/wp-includes/js/wp-embed.min.js
/* ]]&gt; */
&lt;/script&gt;</html><description>printer friendly version ******************************************************************* Brakke Consulting&rsquo;s Animal Health News &amp; Notes for October 21, 2005 Copyright &copy; Brakke Consulting, Inc. &nbsp; Editor: Lynn Fondon, DVM, MBA ******************************************************************* IN THE NEWS: &nbsp; earnings news Elanco Evialis Fort Dodge Heska ImmuCell Intervet Nestle Pfizer Virbac SA &nbsp; other news Adisseo Alpharma Imugene Merial (Imugene) Merial (Igenity) Neogen Nutreco Pingo Poultry Plukon Royale Select Sires &nbsp; ****************************************************************** COMPANY EARNINGS RELEASES &nbsp; &gt; Pfizer reported financial results for the third quarter of 2005.&nbsp; Animal Health revenues were $503 million for the quarter, an increase of 6% compared to the third quarter of 2004.&nbsp; Animal Health revenues for the first nine months of 2005 were $1,576 million, an increase of 14% compared to the first nine months of 2004.&nbsp; (PRNewswire)&nbsp;&nbsp; &nbsp; &gt; Akzo Nobel reported results for the third quarter of 2005.&nbsp; Intervet revenues were up 10% at EUR 277 million ($334 million). Autonomous growth was 9%, while currency translation had a positive effect of 2%. Intervet further expanded its strong market position in Europe due to improved supplies and to strong growth of Cobactan. Sales in North America grew substantially, driven by new product introductions in the companion animal segment, including Vetsulin and Continuum, and in the cattle segment, where the recently introduced cattle biologicals line Vista received very positive response. Sales in LatinView Full Post;</description></oembed>
